Use of corticosteroids for remission induction therapy in patients with new-onset ulcerative colitis in real-world settings

References

• Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255–9.
   PubMed Web of Science ®Google Scholar
• Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J. 1955;2:1041–1048.
   PubMed Web of Science ®Google Scholar
• Summers RW, Switz DM, Sessions JT Jr, et al. National cooperative Crohn’s disease study: results of drug treatment. Gastroenterology. 1979;77:847–869.
   PubMed Web of Science ®Google Scholar
• Powell-Tuck J, Bown RL, Lennard-Jones JE. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol. 1978;13:833–837.
   PubMed Web of Science ®Google Scholar
• Ford AC, Bemstein CN, Kham KL, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:590–599.
   PubMed Web of Science ®Google Scholar
• Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut. 1997;40:775–781.
   PubMed Web of Science ®Google Scholar
• Lennard-Jones JE, Misiewicz JJ, Connel AM, et al. Prednisone as maintenance treatment for ulcerative colitis in remission. Lancet. 1965;1:188–189.
   PubMed Web of Science ®Google Scholar
• Matsuoka K, Kobayashi T, Ueno F, et al. Evidence-based Clinical Practice Guideline for Inflammatory Bowel Disease. J Gastroenterol.  2018;53:305-353.
   Google Scholar
• Benchimol EI, Seow CH, Steinhart AH, et al. Traditional corticosteroids for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2008;16(2):CD006792.
   Web of Science ®Google Scholar
• Curtis JR, Westfall AO, Allison J, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006;55:420–426.
   PubMed Web of Science ®Google Scholar
• Hoes JN, Jacobs JW, Verstappen SM, et al. Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann Rheum Dis. 2009;68:1833–1838.
   PubMed Web of Science ®Google Scholar
• Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effect. Ann Rheum Dis. 2009;68:1119–1124.
   PubMed Web of Science ®Google Scholar
• Strehl C, Bijlsma JWJ, de Wit M, et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis. 2016;75:952–977.
   PubMed Web of Science ®Google Scholar
• Targownik LE, Nugent Z, Singh H, et al. Prevalence of and outcomes associated with corticosteroid prescription in inflammatory bowel disease. Inflammatory Bowel Dis. 2014;20:622–630.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Abreu MT, Cohen R, et al. American gastroenterological association institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:940–987.
   PubMed Web of Science ®Google Scholar
• Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American college of gastroenterology, practice parameters committee. Am J Gastroenterol. 2010;105:501–523.
   PubMed Web of Science ®Google Scholar
• Research study of intractable inflammatory bowel disease by Ministry of Health, Labour and Welfare research group (Suzuki group): Diagnostic criteria and treatment guidelines for ulcerative colitis and Crohn’s disease, Supplemental volume, Annual report; 2016. (revised in July 2017).
   Google Scholar
• Bernstein CN, Blanchard JF, Rawsthorne P, et al. Epidemiology of Crohn’s disease and ulcerative colitis in central Canadian province: a population-based study. Ann J Epidemiol. 1999;149:916–924.
   PubMed Web of Science ®Google Scholar
• Kozyrskj AL, Mustard CA. Validation of an electronic, population-based prescription database. Ann Pharmacother. 1998;32:1152–1157.
   Web of Science ®Google Scholar
• Vestergaard P, Mosekilde L. Fracture risk in patients with celiac disease, Crohn’s disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark. Am J Epidemiol. 2002;156:1–10.
   PubMed Web of Science ®Google Scholar
• Komiyama T, Yajima T, Kubota R, et al. Lower doses of 6-mercaptopurine/azathioprine bring enough clinical efficacy and therapeutic concentration of erythrocyte 6-mercaptopurine metabolite in Japanese IBD patients. J Crohns Colitis. 2008;2:315–321.
   PubMed Web of Science ®Google Scholar
• Kakuta Y, Naito T, Onodera M, et al. NUDT15 R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD. Pharmacogenomics J. 2016;16:280–285.
   PubMed Web of Science ®Google Scholar
• The Medical Procedure Index. Health service bureau, ministry of health, labor and welfare. [cited 2016 Jun 10]. Available from: http://www.iryohoken.go.jp/shinryohoshu/downloadMenu/
   Google Scholar
• Brunton L, Knollman B, Hilal-Dandan R. Goodman and Gilman’s the pharmacological basis of therapeutics. 13th ed. McGraw-Hill Education/Medical Press; 2017.
   Google Scholar
• Fukushima T., editor. Crohn’s and Colitis Foundation of Japan (CCFJ): clinical practice guidelines for ulcerative colitis.  3rd ed., Bunkodo Press; 2016
   Google Scholar
• Andres PG, Friedman LS. Epidemiology and the natural history of inflammatory bowel disease. Gastroenterol Clin North Am. 1999;28:255–281.
   PubMed Web of Science ®Google Scholar
• Sartor RB, Sandborn WJ, et al., Editor. Kirsner's textbook of inflammatory bowel disease. 6th ed., Saunders, 2004;280-288.
   Google Scholar
• Hibi T, Inoue N, Ogata H, et al. Introduction and overview: recent advances in the immunotherapy of inflammatory bowel disease. J Gastroenterol. 2003;38(Suppl):36–42.
   Google Scholar
• Ilntckyj A, Shanahan F, Anton PA, et al. Quantification of the placebo response in ulcerative colitis. Gastroenterology. 1997;112:1854–1858.
   Web of Science ®Google Scholar
• Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6:965–990.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492–509.
   PubMed Web of Science ®Google Scholar
• Solberg IC, Vatn MH, Hoie O, et al. Clinical course in Crohn’s disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007;5:1430–1438.
   PubMed Web of Science ®Google Scholar
• Japan intractable disease inflammation center. [cited 2018 Aug 1]. Available from: http://www.nanbyou.or.jp/entry/62
   Google Scholar